Navigation Links
Arkansas Prostate Cancer Center Earns High Honor of ACR-ASTRO Accreditation
Date:6/11/2012

LITTLE ROCK, Ark., June 11, 2012 /PRNewswire-iReach/ -- The Arkansas Prostate Cancer Center, a partnership between AKSM/Oncology and Arkansas Urology, has earned the high honor of a three-year term of accreditation in radiation oncology. The Arkansas Prostate Cancer Center is one of only a handful of prostate-only treatment centers in United States to earn this distinction.

(Photo: http://photos.prnewswire.com/prnh/20120611/CG22394)

The ACR-ASTRO seal of accreditation represents the highest level of quality and patient safety, and is the result of a recent review by the American College of Radiology (ACR) and The American Society for Radiation Oncology (ASTRO). It is awarded only to facilities meeting specific Practice Guidelines and Technical Standards developed by ACR and ASTRO after a peer-review evaluation by board-certified radiation oncologists and medical physicists who are experts in the field.

"Delivering the highest quality of care has always been a priority for the urologists within Arkansas Urology," said Jack Wang, MD. "This accreditation is not required, but we were determined to undergo this vigorous review to assure we delivered the highest quality of care. We firmly believe being recognized with such distinction demonstrates our commitment to quality and excellence, not only to our patients, but to the greater community as well."

During the Arkansas Prostate Cancer Center's review and on-site survey, patient care and treatment, patient safety, personnel qualifications, adequacy of facility equipment, quality control procedures, and quality assurance programs were assessed. The Arkansas Prostate Cancer Center received an unqualified recommendation which means there were no deficiencies that needed improvement.

AKSM/Oncology both manages and staffs the Arkansas Prostate Cancer Center and is the market leader providing radiation therapy services in conjunction with urologists throughout the United States. AKSM/Oncology spent years planning and creating prostate-only treatment centers in partnership with urologists and radiation oncologists to assure the highest clinical standards and protocols were adopted and implemented. "Clinical quality is an ongoing process that requires diligence and commitment of all the parties," said AKSM/Oncology National Clinical Director Donald Jackson. "We applaud ASTRO for continuing to recognize our prostate-only cancer treatment centers for their clinical excellence and highest level of patient care."

Jackson also stated that prostate cancer patients overwhelmingly support treatment at urology-integrated centers like the Arkansas Prostate Cancer Center (click to see videos), and that additional AKSM/Oncology-operated centers are currently seeking ACR accreditation.

The ACR is a national professional organization serving more than 34,000 diagnostic/interventional radiologists, radiation oncologists, nuclear medicine physicians, and medical physicists with programs focusing on the practice of medical imaging and radiation oncology and the delivery of comprehensive health care services. ASTRO is a professional organization serving more than 10,000 radiation oncologists, medical physicists and other health care professionals involved in the treatment of cancer patients.

AKSM/Oncology is a urologist-owned and operated company that has earned a national reputation for its radiation center expertise. AKSM/Oncology, Inc. is a subsidiary of AKSM, Ltd. a national provider of technology and services by urologist for urologists since 1986.

Arkansas Urology is comprised of 17 urologists and 1 radiation oncologist with locations in Little Rock, North Little Rock, Benton, Clinton, El Dorado, Heber Springs, and Russellville. 

Media Contact: Gary Stelluti Health Care Marketing Strategies, LLC, 614-775-9659, gary@hcmarketing.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Arkansas Prostate Cancer Center
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
2. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
3. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
4. US HIFU to Showcase High Intensity Focused Ultrasound for the Treatment of Prostate Cancer at AUA
5. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
6. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
7. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
8. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
9. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Fourth-quarter 2016 revenues of $1,242 million brings ... of guidance Company reports ... associated with the write-down of goodwill and intangible assets ... Fourth-quarter reported $14.96 diluted (GAAP) ... $14.48 diluted (GAAP) loss per share from continuing operations ...
(Date:2/27/2017)... Halyard Health, Inc. (NYSE: HYH ) ... its 2017 outlook and related key planning assumptions. Executive Summary ... a 2 percent increase compared to the prior year. ... $10 million compared to net income of $15 million in ... was $24 million compared to adjusted net income of $27 ...
(Date:2/27/2017)... 27, 2017  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), ... molecular diagnostic tests and pathology services, announced today the ... upcoming United States and Canadian ... 2017 in San Antonio, Texas . ... data from the Company,s extensive experience in molecular thyroid ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... 2017 , ... Much attention has been paid to the problem of men ... painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain medications ... in male populations.(1) , The proportion of women using illicit drugs is also increasing ...
(Date:2/27/2017)... ... ... Orange County dentist, Dr. A. Rassouli, comments on the new ... bacteria in plaque infect the gums and other tissues supporting the teeth. Treatment typically ... SRP, and can include surgical therapies if the condition has led to significant damage. ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon ... proud to announce a new informational post on robotic hair transplantation. San Francisco ... (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
Breaking Medicine News(10 mins):